Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases
Phase 4
- Conditions
- Convulsive Diseases
- Registration Number
- NCT00796380
- Lead Sponsor
- Shenzhen Children's Hospital
- Brief Summary
The purpose of this study is to evaluate the efficacy of Xingnaojing for the treatment of convulsive diseases; to investigate whether convulsion episodes can be induced or aggravated by Xingnaojing and the role inflammation plays in the process.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
- Febrile convulsion: positive family history of febrile convulsion; aged between 6 months and 6 years old; in accordance with the diagnosis criteria of simple type of febrile convulsion
- Frequent episodes of epilepsy: epilepsy episodes of all types; > 3 times / week
- Refractory epilepsy: no satisfactory efficacy after treatment by 2~3 antiepileptic drugs; ≥ 1 time / month
- Cerebral palsy: all types of cerebral palsy in children less than 3 years old. -
Exclusion Criteria
- Febrile convulsion: family history of epilepsy, complex type of febrile convulsion, epileptic episodes, febrile convulsion plus
- Frequent episodes of epilepsy: combined with advanced diseases
- Refractory epilepsy: epilepsy combined with advanced diseases
- Cerebral palsy: advanced diseases combined with backwardness or retardation of brain function development.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Frequency of convulsive episodes 1 year Antipyretic rate , Frequency of convulsive episodes , one year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Xingnaojing's efficacy in convulsive diseases like epilepsy?
How does Xingnaojing compare to standard anticonvulsants in managing seizure frequency and severity?
Are there specific biomarkers that predict patient response to Xingnaojing treatment in convulsive disorders?
What adverse events are associated with Xingnaojing use in pediatric convulsive disease populations?
What are the potential drug combinations or alternatives to Xingnaojing for treating refractory seizures?